KR20230169093A - 환상 펩타이드 화합물을 포함하는 제제 및 그의 제조 방법 - Google Patents

환상 펩타이드 화합물을 포함하는 제제 및 그의 제조 방법 Download PDF

Info

Publication number
KR20230169093A
KR20230169093A KR1020237032063A KR20237032063A KR20230169093A KR 20230169093 A KR20230169093 A KR 20230169093A KR 1020237032063 A KR1020237032063 A KR 1020237032063A KR 20237032063 A KR20237032063 A KR 20237032063A KR 20230169093 A KR20230169093 A KR 20230169093A
Authority
KR
South Korea
Prior art keywords
compound
composition
formulation
solution
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237032063A
Other languages
English (en)
Korean (ko)
Inventor
다카미쓰 우에토
유카리 구보키
Original Assignee
추가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추가이 세이야쿠 가부시키가이샤 filed Critical 추가이 세이야쿠 가부시키가이샤
Publication of KR20230169093A publication Critical patent/KR20230169093A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237032063A 2021-05-07 2022-05-06 환상 펩타이드 화합물을 포함하는 제제 및 그의 제조 방법 Pending KR20230169093A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JPJP-P-2021-079015 2021-05-07
JP2021079015 2021-05-07
KR1020237001877A KR102582225B1 (ko) 2021-05-07 2022-05-06 환상 펩타이드 화합물을 포함하는 제제 및 그의 제조 방법
PCT/JP2022/019540 WO2022234850A1 (ja) 2021-05-07 2022-05-06 環状ペプチド化合物を含む製剤及びその製造方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237001877A Division KR102582225B1 (ko) 2021-05-07 2022-05-06 환상 펩타이드 화합물을 포함하는 제제 및 그의 제조 방법

Publications (1)

Publication Number Publication Date
KR20230169093A true KR20230169093A (ko) 2023-12-15

Family

ID=83932759

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237032063A Pending KR20230169093A (ko) 2021-05-07 2022-05-06 환상 펩타이드 화합물을 포함하는 제제 및 그의 제조 방법
KR1020237001877A Active KR102582225B1 (ko) 2021-05-07 2022-05-06 환상 펩타이드 화합물을 포함하는 제제 및 그의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237001877A Active KR102582225B1 (ko) 2021-05-07 2022-05-06 환상 펩타이드 화합물을 포함하는 제제 및 그의 제조 방법

Country Status (12)

Country Link
US (1) US20240366711A1 (enExample)
EP (1) EP4299069A4 (enExample)
JP (2) JP7181442B1 (enExample)
KR (2) KR20230169093A (enExample)
CN (1) CN117241817A (enExample)
AU (1) AU2022270498A1 (enExample)
BR (1) BR112023019622A2 (enExample)
CA (1) CA3219090A1 (enExample)
IL (1) IL306018A (enExample)
MX (1) MX2023013099A (enExample)
TW (1) TW202308679A (enExample)
WO (1) WO2022234850A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI579296B (zh) 2011-12-28 2017-04-21 Chugai Pharmaceutical Co Ltd Cyclization of Peptide Compounds
BR112022007535A2 (pt) 2019-11-07 2022-07-12 Chugai Pharmaceutical Co Ltd Composto peptídico cíclico tendo ação inibitória de kras
AR125800A1 (es) 2021-05-07 2023-08-16 Chugai Pharmaceutical Co Ltd Métodos para producir compuestos cíclicos que comprendan residuos de aminoácidos sustituidos con n
KR20250008758A (ko) 2022-05-06 2025-01-15 추가이 세이야쿠 가부시키가이샤 Hras 및 nras에 대한 선택적인 kras 억제 효과를 갖는 고리 화합물
JPWO2024085235A1 (enExample) * 2022-10-20 2024-04-25
AU2024257451A1 (en) * 2023-04-20 2025-10-09 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic peptide compound

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122059A1 (en) 2011-03-04 2012-09-13 New York University Hydrogen bond surrogate macrocycles as modulators of ras
WO2013100132A1 (ja) 2011-12-28 2013-07-04 中外製薬株式会社 ペプチド化合物の環化方法
WO2016071515A1 (en) 2014-11-07 2016-05-12 Sigmoid Pharma Limited Compositions comprising cyclosporin
WO2017181061A1 (en) 2016-04-15 2017-10-19 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
WO2018031730A2 (en) 2016-08-11 2018-02-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide inhibitors of phosphoglycerate mutase and methods of use
WO2018225864A1 (ja) 2017-06-09 2018-12-13 中外製薬株式会社 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ
WO2020122182A1 (ja) 2018-12-12 2020-06-18 中外製薬株式会社 分子内水素結合可能な官能基を有するアミノ酸とそれらのアミノ酸を含むペプチド化合物、およびそれらの製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2670418A4 (en) * 2011-02-04 2015-06-17 Aegis Therapeutics Llc ORAL BIO-AVAILABLE PEPTIDARY MATERIAL COMPOSITIONS AND METHOD THEREFOR
BR112022007535A2 (pt) * 2019-11-07 2022-07-12 Chugai Pharmaceutical Co Ltd Composto peptídico cíclico tendo ação inibitória de kras
AR125800A1 (es) * 2021-05-07 2023-08-16 Chugai Pharmaceutical Co Ltd Métodos para producir compuestos cíclicos que comprendan residuos de aminoácidos sustituidos con n

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122059A1 (en) 2011-03-04 2012-09-13 New York University Hydrogen bond surrogate macrocycles as modulators of ras
WO2013100132A1 (ja) 2011-12-28 2013-07-04 中外製薬株式会社 ペプチド化合物の環化方法
WO2016071515A1 (en) 2014-11-07 2016-05-12 Sigmoid Pharma Limited Compositions comprising cyclosporin
WO2017181061A1 (en) 2016-04-15 2017-10-19 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
WO2018031730A2 (en) 2016-08-11 2018-02-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide inhibitors of phosphoglycerate mutase and methods of use
WO2018225864A1 (ja) 2017-06-09 2018-12-13 中外製薬株式会社 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ
WO2020122182A1 (ja) 2018-12-12 2020-06-18 中外製薬株式会社 分子内水素結合可能な官能基を有するアミノ酸とそれらのアミノ酸を含むペプチド化合物、およびそれらの製造方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Acc. Chem. Res., 2008, 41, 1331-1342.
Adv. Drug Del. Rev. 1997, 23, 3-25.
Angew. Chem. Int. Ed., 2013, 52, 254-269.
Chem. Rev., 2019, 119, 10360-10391.
Future Med. Chem., 2009, 1, 1289-1310.
Ther. Deliv. (2017) 8(10), 867-878.

Also Published As

Publication number Publication date
JP7181442B1 (ja) 2022-11-30
IL306018A (en) 2023-11-01
MX2023013099A (es) 2023-11-17
CA3219090A1 (en) 2022-11-10
KR102582225B1 (ko) 2023-09-22
EP4299069A4 (en) 2025-03-05
JPWO2022234850A1 (enExample) 2022-11-10
TW202308679A (zh) 2023-03-01
US20240366711A1 (en) 2024-11-07
CN117241817A (zh) 2023-12-15
EP4299069A1 (en) 2024-01-03
KR20230020548A (ko) 2023-02-10
JP2023015334A (ja) 2023-01-31
BR112023019622A2 (pt) 2023-11-14
AU2022270498A1 (en) 2023-10-05
WO2022234850A1 (ja) 2022-11-10

Similar Documents

Publication Publication Date Title
KR102582225B1 (ko) 환상 펩타이드 화합물을 포함하는 제제 및 그의 제조 방법
EP2310363B1 (en) Anticancer oral formulation
CN104072486B (zh) 作为丙型肝炎病毒抑制剂的联-1h-苯并咪唑
EP2275419B1 (en) A lubiprostone crystal, its preparation process and its use
ES2929526T3 (es) Sal cristalina de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para su uso en trastornos asociados al receptor S1P1
TWI824384B (zh) 經取代之吡啶并三𠯤化合物及其用途
ES3042390T3 (en) Pyruvate kinase r (pkr) activating compositions
EA027869B1 (ru) Стабилизированная композиция такролимуса
WO2024206817A1 (en) Crystalline forms of a compound for the targeted degradation of the androgen receptor
WO2022017446A1 (zh) Akt抑制剂的单位剂量组合物
CN103509001B (zh) 一种埃索美拉唑镁三水合物及其制备方法
JP2016513676A (ja) 化合物の多形および塩
EP4663198A1 (en) Composition containing cyclic peptide compound and surfactant
EA049912B1 (ru) Препарат, содержащий циклическое пептидное соединение, и способы его приготовления
CN116970027A (zh) 哑铃型两亲性肽类树形分子、合成及其作为药物递送系统的应用
CA2947374A1 (en) Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseases
JP2007512333A (ja) 縮合ピロロカルバゾール含有粒子形成組成物
WO2025240802A1 (en) Novel compositions, devices and methods
WO2025235577A1 (en) Forms and formulations of substituted 3-((3-amino)piperidine-2,6-dione compounds
WO2022161507A1 (zh) Brepocitinib甲苯磺酸盐的晶型及其制备方法和用途
WO2025040810A1 (en) Therapeutic compounds, a method of manufacturing thereof as well as uses thereof
TW202519204A (zh) 前體藥物、包含其的奈米顆粒及其用途
WO2019137027A1 (zh) Galunisertib的晶型及其制备方法和用途
HK1231058A1 (en) 6-chlorine-substituted imidazo[1,2-a]pyridine carboxamides and the use thereof as soluble guanylate cyclase stimulators

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230919

Application number text: 1020237001877

Filing date: 20230117

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250502

Comment text: Request for Examination of Application